Buy & Sell AbbVie Inc (ABBV) – AbbVie Inc Price Today
Aura AI Summary
Key Stats
- $358.55BMarket Cap
- HealthSector
- -16.43%3M Drawdown
- $420.78BEnterprise Value
- 3.41%Dividend Yield
- 91% Buy | 9% SellTrading Activity
- 90 daysTypical Hold Time
AbbVie Inc (ABBV) is currently valued at a market capitalization of $358.55B, with an enterprise value of $420.78B. Over the past 52 weeks, AbbVie Inc has traded between a low of $177.44 and a high of $244.38, highlighting its annual price range. Over the past three months, AbbVie Inc has recorded a drawdown of -16.43%, reflecting recent price volatility. AbbVie Inc offers a dividend yield of 3.41%, with the most recent dividend of $1.73 paid on 15 Apr 26. On average, investors hold AbbVie Inc for approximately 90 days, indicating typical investor behavior on the platform.
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Most Recent News
Investors invited to join Cross Country Healthcare fraud investigation by Schall Law Firm
The Schall Law Firm is investigating Cross Country Healthcare, Inc. for potential securities law violations, including false or misleading statements and failure to disclose important information. Investors who suffered losses are encouraged to parti...
Cohen & Steers updates components in its Global and International Realty Majors Indexes effective May 15, 2026
Cohen & Steers announced changes to its Global Realty Majors Portfolio Index and International Realty Majors Portfolio Index, effective after market close on May 15, 2026. The updates include adding Azrieli Group Ltd. and removing LEG Immobilien AG f...
Atkore director sells shares after mixed Q2 results with earnings beat but lower profit year-over-year.
Atkore Inc. director James Wilbert W Jr. sold 3,299 shares at $73.61 each following the company's Q2 earnings report. The company reported earnings of $1.23 per share, beating estimates but down from $2.04 per share a year ago, while revenue grew to ...